Präsentationen First-in-man trials - how to do them better?

R. Seitz

Safety risks in First-in-Man trials – an overview

871 K

Minimal pre-clinical and toxicological requirements

1.7 M

Predictive value of preclinical animal models

1.9 M

Where and how should First-in-Man Trials

826 K

First-in-Man trials as part of integrated Phase

3.9 M

Germany’s Regulatory Authorities’ approach to approval for First-in- Man trials with new chemical entities (NCEs)

123 K

First-in-man trials with new biotechnology-derived entities

1.4 M

Safety in Phase I

263 K

Seite aktualisiert am 07.02.2007